UroGen Submits NDA for UGN-103 Bladder Cancer Treatment
Princeton, New Jersey — August 17, 2026 UroGen Pharma Ltd. announced the submission of a New Drug Application (NDA)...
NMIBC
Advertisement
Ractigen Therapeutics Closes $31M Financing to Advance saRNA Pipeline
NANTONG, China, July 29, 2026 Ractigen Therapeutics has successfully closed a financing round exceeding $31 million (over RMB 200...
ImmunityBio Receives UAE Marketing Authorization for ANKTIVA
CULVER CITY, Calif., July 29, 2026 ImmunityBio announced that the Emirates Drug Establishment (EDE) has granted Marketing Authorization for...
CG Oncology Publishes Positive Phase 3 BOND-003 Results in The Lancet Oncology
DALLAS, July 27, 2026 CG Oncology, Inc. announced the publication of results from its pivotal Phase 3 BOND-003 Cohort...
UroGen Announces FDA Clearance of IND for UGN-501 in Bladder Cancer
PRINCETON, N.J., July 8, 2026 UroGen Pharma Ltd. announced that the U.S. Food and Drug Administration (FDA) has cleared...
Advertisements
Hamlet BioPharma Advances Alpha1H into Phase 3 Trial
LUND, Sweden, June 17, 2026 Hamlet BioPharma AB has reached a major clinical development milestone with the successful completion...
Hamlet BioPharma Expands Alpha1H Trial for Bladder Cancer
LUND, Sweden, June 22, 2026 Hamlet BioPharma AB has announced a significant expansion of its U.S. clinical development program...
ImmunityBio Highlights ANKTIVA Data in Lung and Bladder Cancer at ASCO 2026
CULVER CITY, Calif., June 1, 2026 ImmunityBio announced new clinical and comparative data from its ANKTIVA® (nogapendekin alfa inbakicept-pmln)...
AstraZeneca’s Imfinzi Wins FDA Approval in NMIBC
CAMBRIDGE, United Kingdom, May 28, 2026 AstraZeneca has achieved a significant milestone in bladder cancer treatment with the U.S....
ImmunityBio’s ANKTIVA Expansion Review Accepted by FDA
CULVER CITY, Calif., May 19, 2026 ImmunityBio announced that the U.S. Food and Drug Administration (FDA) has accepted its...
Advertisement
